Homepage / Certification of Suitability / News and General Information
Certification of Suitability to the Monographs of the European Pharmacopoeia: News & General Information
Certification Monthly Report of Activities
(16/02/12) The Certification of Substances Division (DCEP) will publish on a monthly basis, a report containing some relevant figures relating to its main activities. January 2012 Certification Monthly Report
How to communicate with EDQM Certification Division
(15/02/12) In order to facilitate communication between the EDQM Certification Division (DCEP) and applicants and also to clarify the ways to send documentation, the DCEP has prepared a guideline that underlines the different possibilities for communication being proposed to companies. Please read ‘Communication with EDQM Certification Division’ / PA/PH/CEP (11) 70 for more information.
CEP Suspensions
a) Following inspection of the manufacturing site(s):
| Date | Substance name | CEP Number |
| 08/02/12 | Quinine hydrochloride | CEP 2005-114 |
| 08/02/12 | Quinine sulfate | CEP 2005-117 |
| 08/02/12 | Digoxin | CEP 2009-281 |
| 08/02/12 | Reserpine | CEP 2010-041 |
| 08/02/12 | Colchicine | CEP 2011-016 |
| 07/02/12 | Erythromycin | CEP 2009-267 |
| 07/02/12 | Trimetazidine dihydrochloride | CEP 2007-245 |
| 20/12/11 | Azathioprine | CEP 2001-341 |
| 20/12/11 | Ticlopidine Hydrochloride | CEP 2003-066 |
| 20/12/11 | Haloperidol | CEP 2003-206 |
| 20/12/11 | Risperidone | CEP 2004-135 |
| 20/12/11 | Diphenoxylate Hydrochloride | CEP 2005-084 |
| 20/12/11 | Nifuroxazide | CEP 2006-074 |
|
04/11/11 |
Isosorbide mononitrate, diluted |
CEP 2002-104 |
|
04/11/11 |
Protamine sulfate |
CEP 2000-162 |
| 06/10/11 | Oxytetracycline Dihydrate | CEP 2002-211 |
| 06/10/11 | Oxytetracycline Hydrochloride | CEP 2002-070 |
| 06/10/11 | Oxytetracycline Hydrochloride |
CEP 2001-125 |
b) Due to a failure to comply with a declaration of willingness to be inspected and/or to operate according to EU GMP (e.g. refusal, of inspection, reconstruction/restoration of site(s), to achieve GMP level, and temporary closure):
| Date | Substance name | CEP Number |
|
20/12/11 |
Troxerutin |
CEP 2006-153 |
|
15/09/11 |
Theophylline |
CEP 1998-09 |
c) Upon request from the holder, due to a temporart inability to produce the API under the approved conditions
| Date | Substance name | CEP Number |
| None |
CEP Withdrawals
a) As a result of an inspection of the manufacturing site(s):
| Date | Substance name | CEP Number |
|
08/02/12 |
Quinine sulfate |
CEP 2009-387 |
|
08/02/12 |
Quinine hydrochloride |
CEP 2010-069 |
|
15/09/11 |
Paclitaxel |
CEP 2008-005 |
b) Due to a failure to fulfill the requirements of the CEP procedure with regards to updating the application and complying with GMP:
| Date | Substance name | CEP Number |
|
12/09/11 |
Tiamulin hydrogen fumarate for veterinary us |
CEP 2007-008 |
|
12/09/11 |
Ribavirin |
CEP 2009-257 |
Events
CEP Suspensions & Withdrawals
Read the updates on the latest CEP suspensions and CEP withdrawals
Additional Information & Documentation
List of all assessors (Updated 01/02/2012)
EDQM Policy ‘Suspension or Cancellation of a Certificate of Suitability' PA/PH/CEP (08) 17, R2
7 allée Kastner, CS 30026, F67081 Strasbourg, France - Tel. +33 (0)3 88 41 30 30 - Fax +33 (0)3 88 41 27 71
Created by 2exVia with MasterEdit®